NewAmsterdam Pharma Company NV Warrant

Yahoo Finance • last year

NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer

NAARDEN, the Netherlands and MIAMI, Oct. 23, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines fo... Full story

Yahoo Finance • last year

NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference

NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medi... Full story

Yahoo Finance • last year

NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer

NAARDEN, The Netherlands and MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines fo... Full story

Yahoo Finance • 2 years ago

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

-- Enrollment Completed Several Months Ahead of Schedule, Reflecting Significant Unmet Need and Patient Demand for New Options -- -- Topline Results Expected in 2H 2024 – NAARDEN, the Netherlands and MIAMI, April 24, 2023 (GLOBE NEWSWIR... Full story

Yahoo Finance • 2 years ago

NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors

NAARDEN, the Netherlands and MIAMI, April 03, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on the research and development of transfo... Full story

Yahoo Finance • 2 years ago

NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update

-- Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led by Frazier Healthcare Partners and Bain Capital Life Sciences, extending expected cash runway through 2026 -- -- Announ... Full story